Niels Murawski

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper et al. · The Lancet Oncology · 2011 · 796 citations

Hematological Malignancy, Lymphoid Neoplasia, 6-Year Results +9

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert et al. · The Lancet · 2019 · 244 citations · Full text

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Carsten Müller, Niels Murawski, Martin H. J. Wiesen et al. · Blood · 2012 · 233 citations · Full text

Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma

Gerhard Held, Niels Murawski, Marita Ziepert et al. · Journal of Clinical Oncology · 2014 · 233 citations

Suboptimal dosing of rituximab in male and female patients with DLBCL

Michael Pfreundschuh, Carsten Müller, Samira Zeynalova et al. · Blood · 2013 · 139 citations